ALK and colorectal carcinoma: Additional co-occurring actionable genomic alterations were identified in 5 NTRK fusion-positive patients: CRC (CCDC6-RET fusion), pancreatic (ITSN2-ALK fusion), prostate (PTEN loss, TBL1XR1-PIK3CA fusion), ovarian (PIK3CA mutation) (Supplementary Table S3).